Completed PHASE2 INTERVENTIONAL 1-arm NCT01095926

Pharmacokinetic Study of Doxorubicin in Children With Cancer (Doxo)

Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia

Sponsor: University Hospital Muenster

Conditions Acute Lymphoblastic Leukemia Neuroblastoma Soft Tissue Sarcoma Wilms Tumor

Interventions doxorubicin

Updated 6 times since 2017 Last updated: Jun 27, 2013 Started: May 31, 2010 Primary completion: Feb 28, 2013 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01095926, this PHASE2 trial focuses on Acute Lymphoblastic Leukemia and Neuroblastoma and remains completed. Sponsored by University Hospital Muenster, it has been updated 6 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital Muenster

Data source: University Hospital Muenster

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United Kingdom , Essen, Germany , Frankfurt, Germany , Freiburg im Breisgau, Germany , Kiel, Germany , Leeds, United Kingdom , Lille, France , London, United Kingdom , Manchester, United Kingdom , Marseille, France and 10 more locations